DEXCOM INC (DXCM) Stock Overview
USA - NASDAQ:DXCM - US2521311074 - Common Stock
DXCM Key Statistics, Chart & Performance
The current stock price of DXCM is 67.1 USD. In the past month the price decreased by -10.63%. In the past year, price decreased by -0.28%.
DXCM Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 27.26 | 232.44B | ||
| ISRG | INTUITIVE SURGICAL INC | 54.8 | 158.13B | ||
| BSX | BOSTON SCIENTIFIC CORP | 34.69 | 145.48B | ||
| SYK | STRYKER CORP | 28.72 | 141.08B | ||
| MDT | MEDTRONIC PLC | 17.04 | 120.86B | ||
| BDX | BECTON DICKINSON AND CO | 12.94 | 52.91B | ||
| IDXX | IDEXX LABORATORIES INC | 52.64 | 50.58B | ||
| EW | EDWARDS LIFESCIENCES CORP | 29.67 | 44.77B | ||
| RMD | RESMED INC | 28.3 | 39.57B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 15.55 | 33.08B | ||
| PHG | KONINKLIJKE PHILIPS NVR- NY | 15.96 | 25.83B | ||
| STE | STERIS PLC | 26.11 | 24.53B |
Related stock screener links
About DXCM
Company Profile
DexCom, Inc. is a medical device company, which engages in the design, development, and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. The company is headquartered in San Diego, California and currently employs 10,300 full-time employees. The company went IPO on 2005-04-14. The firm is primarily focused on the design, development, and commercialization of continuous glucose monitoring (CGM), systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. Its products include Dexcom G6, Dexcom G7, Stelo, Dexcom Share, and Dexcom ONE. The firm enables people to take control of health through innovative biosensing technology. Dexcom G6 is its integrated continuous glucose monitoring system (iCGM). Stelo is designed specifically for people with type II diabetes who do not use insulin as the first over-the-counter glucose biosensor in the United States. The Dexcom Share remote monitoring system, offered for use with any Dexcom system, uses an app on the patient’s compatible mobile device. Its Dexcom G7 is for adults and children (2+ years) living with type I or type II diabetes who are on any insulin or medications, at risk of hypoglycemia, and those with gestational diabetes.
Company Info
DEXCOM INC
6340 Sequence Dr
San Diego CALIFORNIA 92121 US
CEO: Kevin R. Sayer
Employees: 10300
Phone: 18582000200
DEXCOM INC / DXCM FAQ
What is the stock price of DEXCOM INC today?
The current stock price of DXCM is 67.1 USD. The price decreased by -1.76% in the last trading session.
What is the ticker symbol for DEXCOM INC stock?
The exchange symbol of DEXCOM INC is DXCM and it is listed on the Nasdaq exchange.
On which exchange is DXCM stock listed?
DXCM stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for DEXCOM INC stock?
35 analysts have analysed DXCM and the average price target is 105.4 USD. This implies a price increase of 57.07% is expected in the next year compared to the current price of 67.1. Check the DEXCOM INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is DEXCOM INC worth?
DEXCOM INC (DXCM) has a market capitalization of 26.31B USD. This makes DXCM a Large Cap stock.
How many employees does DEXCOM INC have?
DEXCOM INC (DXCM) currently has 10300 employees.
What are the support and resistance levels for DEXCOM INC (DXCM) stock?
DEXCOM INC (DXCM) has a resistance level at 75.56. Check the full technical report for a detailed analysis of DXCM support and resistance levels.
Is DEXCOM INC (DXCM) expected to grow?
The Revenue of DEXCOM INC (DXCM) is expected to grow by 15.01% in the next year. Check the estimates tab for more information on the DXCM EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy DEXCOM INC (DXCM) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of DXCM, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of DXCM, evaluating the profitability, health, valuation and growth aspects
- DEXCOM INC (DXCM) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- DEXCOM INC (DXCM) Sales and EPS estimates to see what analysts future expectations are.
- DEXCOM INC (DXCM) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- DEXCOM INC (DXCM) Insider and Institutional Ownership to learn about the owners and their transactions.
- DEXCOM INC (DXCM) Stock Chart to make your own analysis
- DEXCOM INC (DXCM) Latest news and press-releases to stay up to date.
Does DEXCOM INC (DXCM) stock pay dividends?
DXCM does not pay a dividend.
When does DEXCOM INC (DXCM) report earnings?
DEXCOM INC (DXCM) will report earnings on 2025-10-23, after the market close.
What is the Price/Earnings (PE) ratio of DEXCOM INC (DXCM)?
The PE ratio for DEXCOM INC (DXCM) is 39.47. This is based on the reported non-GAAP earnings per share of 1.7 and the current share price of 67.1 USD. Check the full fundamental report for a full analysis of the valuation metrics for DXCM.
What is the Short Interest ratio of DEXCOM INC (DXCM) stock?
The outstanding short interest for DEXCOM INC (DXCM) is 2.84% of its float. Check the ownership tab for more information on the DXCM short interest.
DXCM Technical Analysis
DXCM Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to DXCM. DXCM scores excellent on profitability, but there are some minor concerns on its financial health.
DXCM Financial Highlights
Over the last trailing twelve months DXCM reported a non-GAAP Earnings per Share(EPS) of 1.7. The EPS decreased by -2.86% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 13.29% | ||
| ROA | 7.8% | ||
| ROE | 22.21% | ||
| Debt/Equity | 0.5 |
DXCM Forecast & Estimates
35 analysts have analysed DXCM and the average price target is 105.4 USD. This implies a price increase of 57.07% is expected in the next year compared to the current price of 67.1.
For the next year, analysts expect an EPS growth of 26.84% and a revenue growth 15.01% for DXCM